Real‐life Effectiveness and Safety of Dupilumab in Adult Patients with Moderate‐to‐Severe Atopic Dermatitis

2021 ◽  
Author(s):  
Andac Salman ◽  
Ozlem Apti Sengun ◽  
Meryem Aktas ◽  
Oktay Taşkapan
Keyword(s):  
Atopic Dermatitis ◽  
Real Life ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Life Effectiveness

scholarly journals Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

2019 ◽  
pp. 1-7 ◽  
Author(s):  
M. C. Fargnoli ◽  
M. Esposito ◽  
S. Ferrucci ◽  
G. Girolomoni ◽  
A. Offidani ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life ◽  
Adult Patients ◽  
Severe Atopic Dermatitis

A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

2020 ◽  
pp. 1-4
Author(s):  
M. C. Fargnoli ◽  
M. Esposito ◽  
S. Ferrucci ◽  
G. Girolomoni ◽  
A. Offidani ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life ◽  
Adult Patients ◽  
Severe Atopic Dermatitis

scholarly journals Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID ‐19 pandemic: A single‐center real‐life experience

2020 ◽  
Vol 33 (4) ◽  
Author(s):  
Mariateresa Rossi ◽  
Chiara Rovati ◽  
Mariachiara Arisi ◽  
Simone Soglia ◽  
Piergiacomo Calzavara‐Pinton
Keyword(s):  
Atopic Dermatitis ◽  
Life Experience ◽  
Real Life ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Single Center

scholarly journals Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

2019 ◽  
Vol 99 (9) ◽  
pp. 762-768 ◽  
Author(s):  
L Ariëns ◽  
K Nimwegen ◽  
M Shams ◽  
D Bruin ◽  
J Schaft ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Economic Burden ◽  
Systemic Treatment ◽  
Adult Patients ◽  
Severe Atopic Dermatitis

scholarly journals Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience

2020 ◽  
Vol 9 (3) ◽  
pp. 791 ◽  
Author(s):  
Silvia Ferrucci ◽  
Giovanni Casazza ◽  
Luisa Angileri ◽  
Simona Tavecchio ◽  
Francesca Germiniasi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Rating Scale ◽  
Real Life ◽  
Life Quality ◽  
Depression Scale ◽  
Interleukin 4 ◽  
Severe Atopic Dermatitis ◽  
Single Center

Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients.

scholarly journals Severe Atopic Dermatitis In Spain: A Real-Life Observational Study

2019 ◽  
Vol Volume 15 ◽  
pp. 1393-1401 ◽  
Author(s):  
Antoni Sicras-Mainar ◽  
Ruth Navarro-Artieda ◽  
José C Armario-Hita
Keyword(s):  
Atopic Dermatitis ◽  
Observational Study ◽  
Real Life ◽  
Severe Atopic Dermatitis

15260 Dupilumab treatment in adult patients with moderate to severe atopic dermatitis: A real-world single-center experience from Turkey

2020 ◽  
Vol 83 (6) ◽  
pp. AB144
Author(s):  
Andac Salman ◽  
Meryem Aktas ◽  
Esra Özkürkçü ◽  
Gonca Saraç ◽  
Oktay Taskapan ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Single Center ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document